ClinicalTrials.gg
CompletedNCT05486065Updated Dec 12, 2025Results posted

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

A Phase 2 interventional study of Semaglutide and Placebo in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 130 sites in 5 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
61st of 163
245 · median 104
Started
2022
with 17 others
Phase 2
10 of 163
1 open now
Registered
103rd of 163
by date
Lead sponsor
89 of 163
Novo Nordisk A/S

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 61st largest by enrollment, is one of 18 that started in 2022, is one of 10 in phase 2, and was the 103rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compares how three doses of semaglutide work in participants with type 2 diabetes (T2D) and overweight who are taking metformin. The study will look mainly at how well participant's blood sugar and participant's body weight are controlled when they are taking the study medicine at different doses. Participants will either get semaglutide [2 milligrams (mg), 8 mg, or 16 mg] or semaglutide placebo (a dummy medicine). Participants will take the study medicine with an injection pen called NovoPen®4. The injection pen is a medical tool with a needle used to inject the study medicine under the skin. The study will last for about 52 weeks. Participants will have 13 clinic visits and 4 phone calls.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female.
  • Aged 18-64 years (both inclusive) at the time of signing .
  • Diagnosed with type 2 diabetes mellitus greater than equal to (≥) 180 days prior to the day of screening.
  • Glycosylated () of 7.0 - 10.5 percentage (%) [53 - 91 millimoles per mole (mmol/mol)] (both inclusive).
  • (BMI) ≥ 27.0 kilograms per meter square (kg/m\^2).
  • Stable daily dose(s) ≥ 90 days prior to the day of screening of any metformin formulations.

Exclusion criteria

Exclusion Criteria:

  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to day of screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Renal impairment measured as estimated (eGFR) value of less than (\<) 30 milliliters per minute (mL/min)/1.73 meter square (m\^2) at screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
245 participants (actual)

Study arms

  • Experimental
    Semaglutide 2 mg

    Participants will receive once-weekly semaglutide 2 mg subcutaneous (s.c.) injection.

    Drug: Semaglutide

  • Placebo comparator
    Semaglutide placebo 2 mg

    Participants will receive once-weekly semaglutide placebo 2 mg s.c. injection.

    Drug: Placebo

  • Experimental
    Semaglutide 8 mg

    Participants will receive once-weekly semaglutide 8 mg s.c. injection.

    Drug: Semaglutide

  • Placebo comparator
    Semaglutide placebo 8 mg

    Participants will receive once-weekly semaglutide placebo 8 mg s.c. injection.

    Drug: Placebo

  • Experimental
    Semaglutide 16 mg

    Participants will receive once-weekly semaglutide 16 mg s.c. injection.

    Drug: Semaglutide

  • Placebo comparator
    Semaglutide placebo 16 mg

    Participants will receive once-weekly semaglutide placebo 16 mg s.c. injection.

    Drug: Placebo

Interventions

  • Semaglutide s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.

  • DrugPlacebo

    Semaglutide placebo s.c. injection once-weekly for 40 weeks. Dose gradually increased over 24 weeks, followed by a 16 week maintenance period.

06

What researchers measure

Primary outcomes

  1. Change in Glycated Haemoglobin (HbA1c)

    Change in HbA1c from baseline (week 0) to end of treatment (week 40) is presented.

    Time frame: Baseline (week 0) and End of treatment (week 40)

Secondary outcomes

  1. Change in Body Weight

    Change in body weight from baseline (week 0) to end of treatment (week 40) is presented.

    Time frame: Baseline (week 0) and End of treatment (week 40)

  2. Number of Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant that is temporally associated with use of investigational medicinal products (IMP), whether or not considered related to IMP. AE can therefore be any unfavourable \& unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with use of IMP. TEAE was defined as event that had onset date (or increase in severity) during on-treatment observation period. On treatment observation period data are presented. On-treatment observation period is defined as time points from first drug date until first date of end of data point sets (DPS1) or last administration of randomised treatment +63 days. DPS1 in trial is defined as all observed data points from randomisation until first date of end of study visit or date of death or date of withdrawal of informed consent or contact as defined by investigator for participants that are lost to follow up.

    Time frame: From baseline (week 0) up to end of study (week 49)

  3. Number of Treatment-emergent Severe Hypoglycaemic Episodes

    Number of treatment-emergent severe Hypoglycaemic episodes are presented. Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. On treatment observation period data are presented. On-treatment oberservation period is defined as time points from first drug date until the first date of end of data point sets (DPS1) or last administration of randomised treatment +63 days. DPS1 in trial is defined as all observed data points from randomisation until the first date of end of study visit or date of death or date of withdrawal of informed consent or date of last contact as defined by investigator for participants that are lost to follow up.

    Time frame: From baseline (week 0) up to end of study (week 49)

07

Results

Posted Nov 5, 2024

Participant flow

This study was conducted at 82 active sites in 4 countries, of which 75 sites enrolled participants.

Participant flow — Overall Study
MilestoneSemaglutide 2.0 mgSemaglutide 8.0 mgSemaglutide 16.0 mgPlacebo
Started61626260
Full analysis set61626260
Safety analysis set60606259
Completed56545554
Not completed5876
Withdrew: Withdrawal by subject1543
Withdrew: Lost to follow-up4222
Withdrew: Physician decision0110
Withdrew: Failure to meet randomization criteria0001

Outcome measures

PrimaryChange in Glycated Haemoglobin (HbA1c)

Change in HbA1c from baseline (week 0) to end of treatment (week 40) is presented.

Time frame:
Baseline (week 0) and End of treatment (week 40)
Reported as:
Mean · Percentage-point of HbA1c
Change in Glycated Haemoglobin (HbA1c)
Percentage-point of HbA1cSemaglutide 2.0 mgSemaglutide 8.0 mgSemaglutide 16.0 mgPlacebo
Change in Glycated Haemoglobin (HbA1c)-1.9 ± 1.1-1.8 ± 1.5-2.1 ± 1.5-1.1 ± 1.3
Statistical analysis
  • Semaglutide 2.0 mg vs Placebo · ANCOVA · p = 0.0002 · Treatment difference: -0.82 · 95% CI -1.25 to -0.39
  • Semaglutide 8.0 mg vs Placebo · ANCOVA · p = 0.0003 · Treatment difference: -0.77 · 95% CI -1.19 to -0.35
  • Semaglutide 16.0 mg vs Placebo · ANCOVA · p = <.0001 · Treatment difference: -1.07 · 95% CI -1.50 to -0.64
  • Semaglutide 2.0 mg vs Semaglutide 8.0 mg · ANCOVA · p = 0.8305 · Treatment difference: 0.05 · 95% CI -0.38 to 0.47
  • Semaglutide 8.0 mg vs Semaglutide 16.0 mg · ANCOVA · p = 0.1678 · Treatment difference: -0.30 · 95% CI -0.72 to 0.13
  • Semaglutide 2.0 mg vs Semaglutide 16.0 mg · ANCOVA · p = 0.2445 · Treatment difference: -0.25 · 95% CI -0.67 to 0.17
SecondaryChange in Body Weight

Change in body weight from baseline (week 0) to end of treatment (week 40) is presented.

Time frame:
Baseline (week 0) and End of treatment (week 40)
Reported as:
Mean · Kilogram (kg)
Change in Body Weight
Kilogram (kg)Semaglutide 2.0 mgSemaglutide 8.0 mgSemaglutide 16.0 mgPlacebo
Change in Body Weight-8.9 ± 8.5-10.1 ± 7.4-13.1 ± 8.4-2.3 ± 4.9
SecondaryNumber of Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant that is temporally associated with use of investigational medicinal products (IMP), whether or not considered related to IMP. AE can therefore be any unfavourable \& unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with use of IMP. TEAE was defined as event that had onset date (or increase in severity) during on-treatment observation period. On treatment observation period data are presented. On-treatment observation period is defined as time points from first drug date until first date of end of data point sets (DPS1) or last administration of randomised treatment +63 days. DPS1 in trial is defined as all observed data points from randomisation until first date of end of study visit or date of death or date of withdrawal of informed consent or contact as defined by investigator for participants that are lost to follow up.

Time frame:
From baseline (week 0) up to end of study (week 49)
Reported as:
Number · Events
Number of Treatment-emergent Adverse Events (TEAEs)
EventsSemaglutide 2.0 mgSemaglutide 8.0 mgSemaglutide 16.0 mgPlacebo
Number of Treatment-emergent Adverse Events (TEAEs)43545537
SecondaryNumber of Treatment-emergent Severe Hypoglycaemic Episodes

Number of treatment-emergent severe Hypoglycaemic episodes are presented. Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. On treatment observation period data are presented. On-treatment oberservation period is defined as time points from first drug date until the first date of end of data point sets (DPS1) or last administration of randomised treatment +63 days. DPS1 in trial is defined as all observed data points from randomisation until the first date of end of study visit or date of death or date of withdrawal of informed consent or date of last contact as defined by investigator for participants that are lost to follow up.

Time frame:
From baseline (week 0) up to end of study (week 49)
Reported as:
Number · Episodes
Number of Treatment-emergent Severe Hypoglycaemic Episodes
EpisodesSemaglutide 2.0 mgSemaglutide 8.0 mgSemaglutide 16.0 mgPlacebo
Number of Treatment-emergent Severe Hypoglycaemic Episodes0000

Adverse events

Collected over From baseline (week 0) up to end of study (week 49). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Semaglutide 2.0 mg0/60 (0%)4/60 (6.7%)30/60 (50%)
Semaglutide 8.0 mg0/60 (0%)2/60 (3.3%)48/60 (80%)
Semaglutide 16.0 mg0/62 (0%)1/62 (1.6%)50/62 (80.6%)
Placebo0/59 (0%)2/59 (3.4%)29/59 (49.2%)
Most frequent serious events
Most frequent serious events
EventSemaglutide 2.0 mgSemaglutide 8.0 mgSemaglutide 16.0 mgPlacebo
Pancreatitis acuteGastrointestinal disorders0/600/600/621/59
VertigoEar and labyrinth disorders0/600/600/621/59
Cardiac failure chronicCardiac disorders0/601/600/620/59
Incisional herniaInjury, poisoning and procedural complications1/600/600/620/59
Inguinal herniaGastrointestinal disorders0/601/600/620/59
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/600/600/620/59
Post procedural haemorrhageInjury, poisoning and procedural complications1/600/600/620/59
Vestibular neuronitisInfections and infestations1/600/600/620/59
Cholecystitis acuteHepatobiliary disorders0/600/601/620/59
Most frequent other events
Showing 10 of 28
Most frequent other events
EventSemaglutide 2.0 mgSemaglutide 8.0 mgSemaglutide 16.0 mgPlacebo
NauseaGastrointestinal disorders13/6025/6023/629/59
DiarrhoeaGastrointestinal disorders9/6020/6013/627/59
VomitingGastrointestinal disorders11/6014/6016/624/59
ConstipationGastrointestinal disorders2/608/6012/623/59
HeadacheNervous system disorders2/606/607/628/59
COVID-19Infections and infestations1/608/601/623/59
DizzinessNervous system disorders2/606/603/624/59
Back painMusculoskeletal and connective tissue disorders1/600/606/622/59
FatigueGeneral disorders2/604/606/622/59
Abdominal pain upperGastrointestinal disorders5/605/602/623/59

Baseline characteristics

Age, Continuous
Age, Continuous(years)Semaglutide 2.0 mgSemaglutide 8.0 mgSemaglutide 16.0 mgPlaceboTotal
Mean52.3 ± 7.653.7 ± 7.552.9 ± 8.652.1 ± 9.552.8 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Semaglutide 2.0 mgSemaglutide 8.0 mgSemaglutide 16.0 mgPlaceboTotal
Female27332535120
Male34293725125
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Semaglutide 2.0 mgSemaglutide 8.0 mgSemaglutide 16.0 mgPlaceboTotal
Hispanic or Latino9891339
Not Hispanic or Latino52545347206
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Semaglutide 2.0 mgSemaglutide 8.0 mgSemaglutide 16.0 mgPlaceboTotal
American Indian or Alaska Native00000
Asian11013
Native Hawaiian or Other Pacific Islander00000
Black or African American6114425
White54495655214
More than one race00202
Unknown or Not Reported01001
08

Study locations

130 sites
  • Univ of Alabama Birmingham
    Birmingham, Alabama 35294, United States
  • University of Alabama Birmingham
    Birmingham, Alabama 35294, United States
  • Velocity Clinical Res-Banning
    Banning, California 92220, United States
  • Velocity Clin Res-Chula Vista
    Chula Vista, California 91911, United States
  • Southern California Res Ctr
    Coronado, California 92118, United States
  • Cedars-Sinai Medical Group
    Encino, California 91436, United States
  • Velocity Clin Res Gardena
    Gardena, California 90247, United States
  • Nat Res Inst Huntington Park
    Huntington Park, California 90255, United States
  • Scripps Whittier Diabetes Inst
    La Jolla, California 92037, United States
  • First Valley Med Grp Lancaster
    Lancaster, California 93534, United States
  • Velocity Clin Res Los Angeles
    Los Angeles, California 90017, United States
  • Diabetes Assoc. Med Group
    Orange, California 92868, United States
  • Western University of Health Sciences
    Pomona, California 91766, United States
  • San Diego Family Care_San Diego
    San Diego, California 92111, United States
  • Mills-Peninsula Hlth Services
    San Mateo, California 94401, United States
  • Encompass Clinical Research_Spring Valley
    Spring Valley, California 91978, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Optumcare Clinical Trials,LLC-Golden
    Colorado Springs, Colorado 80906, United States
  • Innovative Research of W FL
    Clearwater, Florida 33756, United States
  • Tampa Bay Medical Research
    Clearwater, Florida 33761, United States
  • Alliance for Multispec Res
    Coral Gables, Florida 33134, United States
  • University Clin Res-Deland
    DeLand, Florida 32720, United States
  • Northeast Research Institute
    Fleming Island, Florida 32003, United States
  • Indago Research & Health Center Inc.
    Hialeah, Florida 33012, United States
  • Northeast Res Inst. Inc.
    Jacksonville, Florida 32204, United States
  • New Life Medical
    Miami, Florida 33130, United States
  • Genesis Research Center, LLC
    Miami, Florida 33155, United States
  • Suncoast Clinical Research, Inc.
    Miami, Florida 33173, United States
  • Reyes Clinical Research, Inc
    Miami, Florida 33174, United States
  • San Marcus Res Clin Miami Lakes
    Miami Lakes, Florida 33014, United States
  • Clinical Neuroscience Solution
    Orlando, Florida 32801, United States
  • Oviedo Medical Research, LLC
    Oviedo, Florida 32765, United States
  • Family Clinical Trials
    Pembroke Pines, Florida 33026, United States
  • Northeast Research Institute
    Saint Augustine, Florida 32080, United States
  • St Johns Center for Clin. Res
    Saint Augustine, Florida 32086, United States
  • Appalachian Clinical Res LLC
    Adairsville, Georgia 30103, United States
  • Urban Family Practice Assoc
    Marietta, Georgia 30067, United States
  • Herman Clinical Research LLC
    Suwanee, Georgia 30024, United States
  • Rocky Mt Clin Res, LLC
    Idaho Falls, Idaho 83404-7596, United States
  • Velocity Clinical Res Boise
    Meridian, Idaho 83642, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Biofortis Clinical Research
    Addison, Illinois 60101, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • West Broadway Clinic
    Council Bluffs, Iowa 51501, United States
  • Iowa Diab & Endo Res Center
    West Des Moines, Iowa 50266, United States
  • Cotton O'Neil Diab & Endo Ctr
    Topeka, Kansas 66606, United States
  • The Research Group of Lexington LLC
    Lexington, Kentucky 40503, United States
  • Norton Healthcare Research Office
    Louisville, Kentucky 40218, United States
  • Barnum Medical Research Inc.
    Natchitoches, Louisiana 71457, United States
  • MedStar Community Clin Res Ctr
    Hyattsville, Maryland 20782, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Endo And Metab Cons
    Rockville, Maryland 20852, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115-5804, United States
  • Aa Mrc Llc
    Flint, Michigan 48504, United States
  • Elite Research Center
    Flint, Michigan 48532, United States
  • Arcturus HC PLC Troy Med Res
    Troy, Michigan 48098, United States
  • Arcturus Healthcare, PLC
    Troy, Michigan 48098, United States
  • StudyMetrix Research LLC
    City of Saint Peters, Missouri 63303, United States
  • Premier Research Inc.
    Trenton, New Jersey 08611, United States
  • AMC Community Endocrinology
    Albany, New York 12203, United States
  • Mid Hudson Med Res-New Windsor
    New Windsor, New York 12553, United States
  • Northport VA Med Ctr Northport
    Northport, New York 11768, United States
  • Southgate Medical Group, LLP
    West Seneca, New York 14224, United States
  • UNC Eastowne Clinical Research Unit
    Chapel Hill, North Carolina 27514, United States
  • Accellacare
    Wilmington, North Carolina 28401, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • Providence Health Partners Ctr
    Dayton, Ohio 45439, United States
  • Advanced Med Res Maumee
    Maumee, Ohio 43537, United States
  • Velocity Clin Res Grants Pass
    Grants Pass, Oregon 97527, United States
  • Velocity Clinical Res Medford
    Medford, Oregon 97504, United States
  • Lycoming Internal Medicine, Inc.
    Jersey Shore, Pennsylvania 17740, United States
  • Thomas Jefferson Univ Di Rsrch Ctr
    Philadelphia, Pennsylvania 19107, United States
  • Clinical Research of Philadelphia
    Philadelphia, Pennsylvania 19114, United States
  • CORE - Temple University
    Philadelphia, Pennsylvania 19140, United States
  • Tower Health
    West Reading, Pennsylvania 19611, United States
  • Velocity Clinical Research Columbia
    Columbia, South Carolina 29204, United States
  • Velocity Clinical Research Greenville
    Greenville, South Carolina 29615, United States
  • Coastal Carolina Res Ctr
    Mt. Pleasant, South Carolina 29464, United States
  • Trial Management Associates
    Myrtle Beach, South Carolina 29572, United States
  • Palmetto Clinical Research
    Summerville, South Carolina 29485, United States
  • Velocity Clinical Research Union
    Union, South Carolina 29379, United States
  • Chattanooga Medical Research, LLC
    Chattanooga, Tennessee 37404, United States
  • Murphy Research Center
    Humboldt, Tennessee 38343, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Clinical Neuroscience Solutions
    Memphis, Tennessee 38119, United States
  • Amarillo Med Spec LLP
    Amarillo, Texas 79106, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • UT Southwestern Med Cntr
    Dallas, Texas 75390-9302, United States
  • Quality Research Inc
    San Antonio, Texas 78209, United States
  • Briggs Clinical Research, LLC
    San Antonio, Texas 78224, United States
  • VIP Trials
    San Antonio, Texas 78230, United States
  • DCT-Stone Oak
    San Antonio, Texas 78258, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Dwayne O. Williams, M.D., P.A.
    Sugar Land, Texas 77479, United States
  • Hillcrest Family Health Center
    Waco, Texas 76708, United States
  • Nova Health Management & Research Group, PC
    Herndon, Virginia 20171, United States
  • Dominion Medical Associates
    Richmond, Virginia 23219, United States
  • Amherst Family Practice P.C.
    Winchester, Virginia 22601, United States
  • Velocity Clinical Research Spokane
    Spokane, Washington 99203, United States
  • St. Vincent Hosp-Prevea Health
    Green Bay, Wisconsin 54303, United States

Showing the first 100 of 130 sites across 5 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Oct 2023, 14 months.

Results were first posted in Nov 2024, 1 year after primary completion.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 14 months is close to that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2022
First posted
Aug 3, 2022
StartActual
Aug 8, 2022
Primary completionActual
Oct 12, 2023
CompletionActual
Dec 13, 2023
Results first posted
Nov 5, 2024
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05486065
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 3, 2022
Start date
Aug 8, 2022
Primary completion
Oct 12, 2023
Completion
Dec 13, 2023
Results posted
Nov 5, 2024
Last update
Dec 12, 2025

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion